Dose Escalation and Quality of Life in Patients With Localized Prostate Cancer Treated With Radiotherapy: Long-Term Results of the Dutch Randomized Dose-Escalation Trial (CKTO 96-10 Trial)

Late Toxicity and Quality of Life

“…Hoskin et al, for example, reported on their randomized study applying combined hypofractionated 3D-CRT and HDR brachytherapy (Hoskin et al 2013) and described no significant or clinically relevant global HRQOL impairments after a follow-up of 10.5 years. Another published randomized trial treating patients with normofractionated 3D-CRT to total doses of 68 Gy versus 78 Gy found clinically relevant deterioration of HRQOL scales only in the highdose arm with regard to role and physical functioning, whereas there was no significant or clinically relevant deterioration in the corresponding scales of the low-dose arm (Al-Mamgani et al 2011). However, the follow-up of about 36 months in this study is still short.…”

“…Within the last decades, an evolution of HRQOL assessment took place from not considering HRQOL in general at all to meanwhile excessively sampling "HRQOL data" using multiple often institutional and not validated questionnaires in a retrospective manner. In the last years, HRQOL studies started to became more conformal using with increased frequency established and validated questionnaires within prospective studies and-in a few caseseven in the randomized setting (Al-Mamgani et al 2011;Hoskin et al 2013). Nevertheless, due to the large variations within the published literature regarding the endpoints, study design, treatment details, and modalities as well as the used measures and toxicity scores, it would go beyond the scope of this chapter to give a comprehensive summary on this topic.…”

Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysis

“…We added another 18 articles from reviews, for 222 full-text articles assessed for eligibility. Finally, after excluding 161 articles, 61 reports assessing results of 27 RCTs (Zagars et al , 1988; Pilepich et al , 1995; Shipley et al , 1995; Pollack et al , 1996; Bolla et al , 1997; Lawton et al , 1997; Pilepich et al , 1997; Granfors et al , 1998; Nguyen et al , 1998; Pollack et al , 2000; Storey et al , 2000; Lawton et al , 2001; Pilepich et al , 2001; Bolla et al , 2002; Pollack et al , 2002; Hanks et al , 2003; Lamb et al , 2003; Yeoh et al , 2003; Ataman et al , 2004; Beckendorf et al , 2004; Crook et al , 2004; D'Amico et al , 2004; Laverdiere et al , 2004; Christie et al , 2005; Dearnaley et al , 2005; Denham et al , 2005; Lawton et al , 2005; Lukka et al , 2005; Peeters et al , 2005; Pilepich et al , 2005; Sathya et al , 2005; Zietman et al , 2005; Granfors et al , 2006; Peeters et al , 2006; Yeoh et al , 2006; Dearnaley et al , 2007; Al-Mamgani et al , 2008; D'Amico et al , 2008; Horwitz et al , 2008; Kuban et al , 2008; Roach et al , 2008; Bolla et al , 2009; Crook et al , 2009; Marzi et al , 2009; Strigari et al , 2009; Norkus et al , 2009a, 2009b; Alexander et al , 2010; Arcangeli et al , 2010; Bolla et al , 2010; Heemsbergen et al , 2010; Zietman et al , 2010; Al-Mamgani et al , 2011; Arcangeli et al , 2011; Armstrong et al , 2011; Beckendorf et al , 2011; Denham et al , 2011; Jones et al , 2011; Yeoh et al , 2011; Arcangeli et al , 2012; Dearnaley et al , 2012) were used in the network meta-analysis, for 13 364 patients with local or locally advanced prostate cancer randomly assigned to receive one of the seven RT regimens examined (Figures 1...…”

Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer

“…A Dutch randomized study by Peeters et al also showed a benefit in biochemical or clinical progression-free survival with 78 Gy over 68 Gy in 664 men. 19,20 Seven-year freedom from failure was 56% for 78 Gy and 45% for 68 Gy. Zietman et al randomized 393 men with cT1b-T2b disease to 70.2 Gy or 79.2 Gy using combined photon and proton EBRT.…”